Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers

Seminars in Oncology

Volumn 43, Issue 6, 2016, Pages 638-646

  Grigg, Claud ^a   Blake, Zoë ^b   Gartrell, Robyn ^b   Sacher, Adrian ^a   Taback, Bret ^a   Saenger, Yvonne ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b Department of Medicine   (United States)

Author keywords

HSV 1; Immunotherapy; Melanoma; Oncolytic virus; T Vec

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERPESVIRUS VECTOR; MONOCLONAL ANTIBODY; TALIMOGENE LAHERPAREPVEC; GAMMA 34.5 PROTEIN, HUMAN HERPESVIRUS 1; ICP47 PROTEIN, HERPES SIMPLEX VIRUS; IMMEDIATE EARLY PROTEIN; VIRAL PROTEIN;

CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; COMBINATION DRUG THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HERPES SIMPLEX VIRUS 1; HUMAN; MALIGNANT NEOPLASM; MELANOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC THERAPY; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ADVERSE EFFECTS; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES;

GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HERPESVIRUS 1, HUMAN; HUMANS; IMMEDIATE-EARLY PROTEINS; IMMUNOTHERAPY; MELANOMA; NEOPLASMS; ONCOLYTIC VIROTHERAPY; VIRAL PROTEINS;

EID: 85007580007     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2016.10.005     Document Type: Review

References (65)

1. [1] Levaditi, C., Nicolau, S., Sur le culture du virus vaccinal dans les neoplasmes epithelieux. CR Soc Biol, 86, 1922, 928.
2. [2] Kelly, E., Russell, S.J., History of oncolytic viruses: genesis to genetic engineering. Mol Ther 15:4 (2007), 651–659.
3. [3] MacLean, A.R., ul-Fareed, M., Robertson, L., Harland, J., Brown, S.M., Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the ׳a׳ sequence. J Gen Virol 72 (1991), 631–639.
4. [4] Mineta, T., Rabkin, S.D., Yazaki, T., Hunter, W.D., Martuza, R.L., Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1:9 (1995), 938–943.
5. [5] Martuza, R.L., Malick, A., Markert, J.M., Ruffner, K.L., Coen, D.M., Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science (New York, NY) 252:5007 (1991), 854–856.
6. [6] Coffin, R., Interview with Robert Coffin, inventor of T-VEC: the first oncolytic immunotherapy approved for the treatment of cancer. Immunotherapy 8:2 (2016), 103–106.
7. [7] Roizman, B., Knipe, D.M., Whitley, R.J., Herpes simplex viruses. Knipe, D.M., Howley, P.M., (eds.) Fields virology, 2013, Lippincott Williams & Wilkins, Philadelphia, 1823–1897.
8. [8] Preston, C.M., Efstathiou, S., Molecular basis of HSV latency and reactivation. Arvin, A., Campadelli-Fiume, G., Mocarski, E., (eds.) Human herpesviruses: biology, therapy, and immunoprophylaxis, 2007, Cambridge University Press, Cambridge, 1–25.
9. [9] Peters, C., Rabkin, S.D., Designing herpes viruses as oncolytics. Mol Ther Oncolytics 2 (2015), 15010–15044.
10. [10] Rock, D.L., Fraser, N.W., Detection of HSV-1 genome in central nervous system of latently infected mice. Nature 302:5908 (1983), 523–525.
11. [11] Efstathiou, S., Minson, A.C., Field, H.J., Anderson, J.R., Wildy, P., Detection of herpes simplex virus-specific DNA sequences in latently infected mice and in humans. J Virol 57:2 (1986), 446–455.
12. [12] Herrlinger, U., Kramm, C.M., Aboody-Guterman, K.S., et al. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Ther 5:6 (1998), 809–819.
13. [13] Chahlavi, A., Rabkin, S., Todo, T., Sundaresan, P., Martuza, R., Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther 6:10 (1999), 1751–1758.
14. [14] Delman, K.A., Bennett, J.J., Zager, J.S., et al. Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum Gene Ther 11:18 (2000), 2465–2472.
15. [15] Lambright, E.S., Kang, E.H., Force, S., et al. Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model. Mol Ther 2:4 (2000), 387–393.
16. [16] Gujar, S.A., Lee, P.W., Oncolytic virus-mediated reversal of impaired tumor antigen presentation. Front Oncol, 4, 2014, 77.
17. [17] Malmgaard, L., Melchjorsen, J., Bowie, A.G., Mogensen, S.C., Paludan, S.R., Viral activation of macrophages through TLR-dependent and -independent pathways. J Immunol 173:11 (2004), 6890–6898.
18. [18] Rasmussen, S.B., Sorensen, L.N., Malmgaard, L., et al. Type I interferon production during herpes simplex virus infection is controlled by cell-type-specific viral recognition through Toll-like receptor 9, the mitochondrial antiviral signaling protein pathway, and novel recognition systems. J Virol 81:24 (2007), 13315–13324.
19. [19] Reske, A., Pollara, G., Krummenacher, C., Katz, D.R., Chain, B.M., Glycoprotein-dependent and TLR2-independent innate immune recognition of herpes simplex virus-1 by dendritic cells. J Immunol 180:11 (2008), 7525–7536.
20. [20] Kurt-Jones, E.A., Chan, M., Zhou, S., et al. Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc Natl Acad Sci U S A 101:5 (2004), 1315–1320.
21. [21] Krug, A., Luker, G.D., Barchet, W., Leib, D.A., Akira, S., Colonna, M., Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9. Blood 103:4 (2004), 1433–1437.
22. [22] Chew, T., Taylor, K.E., Mossman, K.L., Innate and adaptive immune responses to herpes simplex virus. Viruses 1:3 (2009), 979–1002.
23. [23] Vasilakos, J.P., Michael, J.G., Herpes simplex virus class I-restricted peptide induces cytotoxic T lymphocytes in vivo independent of CD4+ T cells. J Immunol 150:6 (1993), 2346–2355.
24. [24] Zawatzky, R., Hilfenhaus, J., Marcucci, F., Kirchner, H., Experimental infection of inbred mice with herpes simplex virus type 1. I. Investigation of humoral and cellular immunity and of interferon induction. J Gen Virol 53 (1981), 31–38.
25. [25] Liu, B.L., Robinson, M., Han, Z.Q., et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 10:4 (2003), 292–303.
26. [26] He, B., Gross, M., Roizman, B., The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci U S A 94:3 (1997), 843–848.
27. [27] Kaufman, R.J., Double-stranded RNA-activated protein kinase mediates virus-induced apoptosis: a new role for an old actor. Proc Natl Acad Sci U S A 96:21 (1999), 11693–11695.
28. [28] He, Y., Correa, A.M., Raso, M.G., et al. The role of PKR/eIF2alpha signaling pathway in prognosis of non-small cell lung cancer. PLoS One, 6(11), 2011, e24855.
29. [29] Hii, S.I., Hardy, L., Crough, T., et al. Loss of PKR activity in chronic lymphocytic leukemia. Int J Cancer 109:3 (2004), 329–335.
30. [30] Shimada, A., Shiota, G., Miyata, H., et al. Aberrant expression of double-stranded RNA-dependent protein kinase in hepatocytes of chronic hepatitis and differentiated hepatocellular carcinoma. Cancer Res 58:19 (1998), 4434–4438.
31. [31] Todo, T., Martuza, R.L., Rabkin, S.D., Johnson, P.A., Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A 98:11 (2001), 6396–6401.
32. [32] Poppers, J., Mulvey, M., Khoo, D., Mohr, I., Inhibition of PKR activation by the proline-rich RNA binding domain of the herpes simplex virus type 1 Us11 protein. J Virol 74:23 (2000), 11215–11221.
33. [33] Grabstein, K.H., Urdal, D.L., Tushinski, R.J., et al. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science (New York, NY) 232:4749 (1986), 506–508.
34. [34] Eisenberger, A., Elliott, B.M., Kaufman, H.L., Viral vaccines for cancer immunotherapy. Hematol Oncol Clin North Am 20:3 (2006), 661–687.
35. [35] Butterfield, L.H., Cancer vaccines. BMJ, 350, 2015, h988.
36. [36] Melero, I., Gaudernack, G., Gerritsen, W., et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol 11:9 (2014), 509–524.
37. [37] Slingluff, C.L. Jr., Petroni, G.R., Olson, W.C., et al. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res 15:22 (2009), 7036–7044.
38. [38] Eager, R., Nemunaitis, J., GM-CSF gene-transduced tumor vaccines. Mol Ther 12:1 (2005), 18–27.
39. [39] Amgen, Biological license application for talimogene laherparepvec. ODAC Meeting: Amgen Inc, 2015.
40. [40] Hu, J.C., Coffin, R.S., Davis, C.J., et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 12:22 (2006), 6737–6747.
41. [41] Senzer, N.N., Kaufman, H.L., Amatruda, T., et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 27:34 (2009), 5763–5771.
42. [42] Andtbacka, R.H., Kaufman, H.L., Collichio, F., et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33:25 (2015), 2780–2788.
43. [43] Senzer, N., Bedell, C., Horvath, S., Nemunaitis, J., Systemic benefit of GM-CSF-encoding, Oncolytic herpes virus (talimogene laherparepvec, T-VEC) in metastatic melanoma: phase II assessment. Ann Oncol 25:suppl 4 (2014), iv361–iv372 (abstract 1059P).
44. [44] Andtbacka, R.H.I., Kaufman, H.L., Collichio, F., et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 23 (2015), 2780–2788.
45. [45] Kaufman, H.L., Ruby, C.E., Hughes, T., Slingluff, C.L. Jr, Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer, 2, 2014, 11.
46. [46] Ross, M., Andtbacka, R., Puzanov, I., et al. Patterns of durable response with intralesional talimogene laherparepvec (T-VEC): results from a phase III trial in patients with stage IIIb-IV melanoma. J Clin Oncol, 32, 2014, 5s suppl; abstr 9026.
47. [47] Andtbacka, R.H., Ross, M., Puzanov, I., et al. Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial. Ann Surg Oncol 23 (2016), 4169–4177.
48. [48] Kaufman, H.L., Amatruda, T., Reid, T., et al. Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. J Immunother Cancer, 4, 2016, 12.
49. [49] Kaufman, H.L., Kim, D.W., DeRaffele, G., Mitcham, J., Coffin, R.S., Kim-Schulze, S., Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 17:3 (2010), 718–730.
50. [50] Ranki, T., Pesonen, S., Hemminki, A., et al. Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers. J Immunother Cancer, 4, 2016, 17.
51. [51] Kim, M.K., Breitbach, C.J., Moon, A., et al. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. Sci Translat Med, 5(185), 2013 185ra63-ra63.
52. [52] Garon, E.B., Rizvi, N.A., Hui, R., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:21 (2015), 2018–2028.
53. [53] Borghaei, H., Paz-Ares, L., Horn, L., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:17 (2015), 1627–1639.
54. [54] Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:1 (2015), 23–34.
55. [55] Puzanov, I., Milhem, M., Andtbacka, R., et al. Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J Clin Oncol, 2015, 33:suppl abstr 9063.
56. [56] Puzanov, I., Milhem, M.M., Minor, D., et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol 34 (2016), 2619–2626.
57. [57] Hodi, F.S., O׳Day, S.J., McDermott, D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:8 (2010), 711–723.
58. [58] Puzanov, I., Milhem, M., Andtbacka, R., et al. Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J Clin Oncol, 32, 2014, 5s suppl; abstr 9029.
59. [59] Long, G.V., Dummer, R., Ribas, A., et al. Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. J Clin Oncol, 34(suppl), 2016 abstr 9568.
60. [60] Chang, K.J., Senzer, N., Binmoeller, K., Goldsweig, H., Coffin, R., Phase I dose-escalation study of talimogene laherparepvec (T-VEC) for advanced pancreatic cancer (ca). J Clin Oncol, 30, 2012 (suppl; abstr e14546).
61. [61] Apetoh, L., Ladoire, S., Coukos, G., Ghiringhelli, F., Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?. Ann Oncol 26 (2015), 1813–1823.
62. [62] Bracci, L., Schiavoni, G., Sistigu, A., Belardelli, F., Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 21:1 (2014), 15–25.
63. [63] Harrington, K.J., Hingorani, M., Tanay, M.A., et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res 16:15 (2010), 4005–4015.
64. [64] Coit, D.G., Thompson, J.A., Algazi, A., et al. Melanoma, version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Network 14:4 (2016), 450–473.
65. [65] Andtbacka, R.H.I., Collichio, F.A., Amatruda, T., et al. OPTiM: a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. ASCO Meeting Abstracts, 31(15 suppl), 2013, LBA9008.